Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be used to support future coverage determinations and reimbursement policies for enVVeno Medical's enVVe non-surgical replacement venous valve

Publication Highlights:

Peer-reviewed publication in the Journal of Vascular Surgery: Venous and Lymphatic Disorders

More than $32,000 projected healthcare savings per patient over five years

Approximately 2.2 fewer venous ulcers per patient compared to standard of care

Approximately $4,100 projected cost savings per each rVCSS* point of clinical improvement

Economically dominant versus compression therapy and wound care in the modeled analysis

Approximately $5.9 billion estimated annual healthcare savings with broader adoption of effective venous valve replacement therapy

*rVCSS (revised Venous Clinical Severity Score) is a validated clinical tool used to evaluate disease severity and treatment response in patients with chronic venous disease.

IRVINE, CA / ACCESS Newswire / August 4, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today highlighted the publication of a landmark, peer-reviewed health economic analysis in the Journal of Vascular Surgery: Venous and Lymphatic Disorders demonstrating the potential clinical and economic benefits of venous valve replacement therapy for patients with severe deep venous reflux.

The publication titled, "Cost-effectiveness of a prosthetic venous valve versus compression therapies and wound care for treatment of infra-inguinal deep vein reflux," concluded that venous valve replacement therapy has the potential to improve patient outcomes while reducing overall healthcare costs compared with current conservative management. The analysis found that VenoValve, enVVeno's first-generation surgical venous valve technology, was economically dominant versus standard of care over a five-year period, projecting average healthcare savings of more than $32,000 per patient, avoidance of approximately 2.2 venous ulcers per patient, improved quality-adjusted life years (QALYs), and lower overall healthcare costs. The study also projected that treatment became cost-effective by approximately Year 2 and generated net healthcare savings between Years 2 and 3. These findings provide important health economic support for the therapeutic potential of enVVeno's next-generation enVVe® device, which is currently being studied in the TAVVE pivotal trial.

The peer-reviewed publication further highlighted the significant burden of chronic deep venous insufficiency and estimated that broader adoption of effective venous valve replacement therapy could translate into approximately $5.9 billion in annual healthcare savings, underscoring the substantial clinical and commercial opportunity for therapies that address the underlying cause of deep venous disease.